Ads
related to: spinraza- Evrysdi® Benefits & Risks
Learn About The Potential
Benefits & Risks Of Evrysdi
- Taking Evrysdi®
Learn About A Therapy Option
& How It May Help Patients
- Side Effects
Visit The Official Site To Learn
More About Safety & Side Effects
- Learn About Community
Perspectives By Watching Videos
Featuring People Who Take Evrysdi®
- Evrysdi® Oral Therapy
Non-Invasive At-Home Treatment
Delivered To Your Door
- Safety Information
View Important Safety
Information For Evrysdi
- Evrysdi® Benefits & Risks
Search results
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
Zacks via Yahoo Finance· 10 months agoIonis Pharmaceuticals IONS reported a loss of 60 cents per share for second-quarter 2023, which was...
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Zacks via Yahoo Finance· 1 month agoIonis Pharmaceuticals IONS reported a loss of 98 cents per share for first-quarter 2024, which was...
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
Zacks via Yahoo Finance· 9 months agoRoche RHHBY announced that the European Commission (“EC”) had approved the label expansion for...
Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for Biogen Inc. (BIIB). Shares have lost about...
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
Zacks via Yahoo Finance· 3 months agoIt has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added...
Biogen Is Suffering From Doubts About the Future
GuruFocus.com via Yahoo Finance· 2 months agoBiogen Inc. (NASDAQ:BIIB) is an American biopharmaceutical company specializing in the development and commercialization of biosimilars and medicines...
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
Zacks via Yahoo Finance· 2 years agoBiogen BIIB reported second-quarter 2022 earnings per share (EPS) of $5.25, which significantly beat...
Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up
Zacks via Yahoo Finance· 1 year agoBiogen BIIB reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05, beating the...
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
Zacks via Yahoo Finance· 2 years agoIonis Pharmaceuticals IONS reported a loss of 33 cents per share in third-quarter 2022, narrower...
Will Biogen (BIIB) Beat Estimates This Earnings Season?
Zacks via Yahoo Finance· 1 year agoWe expect Biogen BIIB to beat expectations when it reports fourth-quarter and full-year 2022 results...
Ads
related to: spinraza
